{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T07:39:04Z","timestamp":1768635544105,"version":"3.49.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T00:00:00Z","timestamp":1623024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Respiratory syncytial virus (RSV) is a public health concern that causes acute lower respiratory tract infection. So far, no vaccine candidate under development has reached the market and the only licensed product to prevent RSV infection in at-risk infants and young children is a monoclonal antibody (Synagis<jats:sup>\u00ae<\/jats:sup>). Polyclonal human anti-RSV hyper-immune immunoglobulins (Igs) have also been used but were superseded by Synagis<jats:sup>\u00ae<\/jats:sup> owing to their low titer and large infused volume. Here we report a new drug class of immunoglobulins, derived from human non hyper-immune plasma that was generated by an innovative bioprocess, called Ig cracking, combining expertises in plasma-derived products and affinity chromatography. By using the RSV fusion protein (F protein) as ligand, the Ig cracking process provided a purified and concentrated product, designated hyper-enriched anti-RSV IgG, composed of at least 15-20% target-specific-antibodies from normal plasma. These anti-RSV Ig displayed a strong <jats:italic>in vitro<\/jats:italic> neutralization effect on RSV replication. Moreover, we described a novel prophylactic strategy based on local nasal administration of this unique hyper-enriched anti-RSV IgG solution using a mouse model of infection with bioluminescent RSV. Our results demonstrated that very low doses of hyper-enriched anti-RSV IgG can be administered locally to ensure rapid and efficient inhibition of virus infection. Thus, the general hyper-enriched Ig concept appeared a promising approach and might provide solutions to prevent and treat other infectious diseases.<\/jats:p><jats:sec><jats:title>Importance<\/jats:title><jats:p>Respiratory Syncytial Virus (RSV) is the major cause of acute lower respiratory infections in children, and is also recognized as a cause of morbidity in the elderly. There are still no vaccines and no efficient antiviral therapy against this virus. Here, we described an approach of passive immunization with a new class of hyper-enriched anti-RSV immunoglobulins (Ig) manufactured from human normal plasma. This new class of immunoglobulin plasma derived product is generated by an innovative bioprocess, called Ig cracking, which requires a combination of expertise in both plasma derived products and affinity chromatography. The strong efficacy in a small volume of these hyper-enriched anti-RSV IgG to inhibit the viral infection was demonstrated using a mouse model. This new class of immunoglobulin plasma-derived products could be applied to other pathogens to address specific therapeutic needs in the field of infectious diseases or even pandemics, such as COVID-19.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.683902","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T06:47:10Z","timestamp":1623048430000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Hyper-Enriched Anti-RSV Immunoglobulins Nasally Administered: A Promising Approach for Respiratory Syncytial Virus Prophylaxis"],"prefix":"10.3389","volume":"12","author":[{"given":"Emilie","family":"Jacque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Chottin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphn\u00e9","family":"Laubreton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Nogre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Ferret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"de Marcos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Baptista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carole","family":"Drajac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Mondon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"De Romeuf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Rameix-Welti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"El\u00e9ou\u00ebt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sami","family":"Chtourou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Riffault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00e9rald","family":"Perret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphyne","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02150-z","article-title":"Intravenous Immunoglobulin Therapy: A Snapshot for the Internist","volume":"14","author":"Vitiello","year":"2019","journal-title":"Intern Emerg Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"Inter-University Working Party for the Study of Immune: The Effect of Two Different Dosages of Intravenous Immunoglobulin on the Incidence of Recurrent Infections in Patients With Primary Hypogammaglobulinemia. A Randomized, Double-Blind, Multicenter Crossover Trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1080\/14787210.2017.1328278","article-title":"Use of Human Immunoglobulins as an Anti-Infective Treatment: The Experience So Far and Their Possible Re-Emerging Role","volume":"15","author":"Bozzo","year":"2017","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2018.04.024","article-title":"Monoclonal Antibodies as Anti-Infective Products: A Promising Future","volume":"25","author":"Pelfrene","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq100","article-title":"Analysis of Respiratory Syncytial Virus Preclinical and Clinical Variants Resistant to Neutralization by Monoclonal Antibodies Palivizumab and\/or Motavizumab","volume":"203","author":"Zhu","year":"2011","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nature09385","article-title":"Polyreactivity Increases the Apparent Affinity of anti-HIV Antibodies by Heteroligation","volume":"467","author":"Mouquet","year":"2010","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30938-8","article-title":"Global, Regional, and National Disease Burden Estimates of Acute Lower Respiratory Infections Due to Respiratory Syncytial Virus in Young Children in 2015: A Systematic Review and Modelling Study","volume":"390","author":"Shi","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30721-4","article-title":"Causes of Severe Pneumonia Requiring Hospital Admission in Children Without HIV Infection From Africa and Asia: The PERCH Multi-Country Case-Control Study","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/apa.12662","article-title":"Adults Face Increased Asthma Risk After Infant RSV Bronchiolitis and Reduced Respiratory Health-Related Quality of Life After RSV Pneumonia","volume":"103","author":"Backman","year":"2014","journal-title":"Acta Paediatr"},{"key":"B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12879-018-3002-3","article-title":"Burden of Severe RSV Disease Among Immunocompromised Children and Adults: A 10 Year Retrospective Study","volume":"18","author":"Chatzis","year":"2018","journal-title":"BMC Infect Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1186\/s12879-015-1218-z","article-title":"Modelling Estimates of the Burden of Respiratory Syncytial Virus Infection in Adults and the Elderly in the United Kingdom","volume":"15","author":"Fleming","year":"2015","journal-title":"BMC Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-015-0258-9","article-title":"Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem","volume":"32","author":"Branche","year":"2015","journal-title":"Drugs Aging"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory Syncytial Virus (RSV): A Scourge From Infancy to Old Age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14158","article-title":"Potent Single-Domain Antibodies That Arrest Respiratory Syncytial Virus Fusion Protein in its Prefusion State","volume":"8","author":"Rossey","year":"2017","journal-title":"Nat Commun"},{"key":"B15","article-title":"Respiratory Syncytial Virus and Metapneumovirus","volume-title":"Fields Virology","author":"Collins","year":"2007"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00555-11","article-title":"Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes","volume":"85","author":"McLellan","year":"2011","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.1234914","article-title":"Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody","volume":"340","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2017.03.012","article-title":"Vaccine Development for Respiratory Syncytial Virus","volume":"23","author":"Graham","year":"2017","journal-title":"Curr Opin Virol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"eaaj1879","DOI":"10.1126\/sciimmunol.aaj1879","article-title":"Rapid Profiling of RSV Antibody Repertoires From the Memory B Cells of Naturally Infected Adult Donors","volume":"1","author":"Gilman","year":"2016","journal-title":"Sci Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"5104","DOI":"10.1038\/ncomms6104","article-title":"Visualizing the Replication of Respiratory Syncytial Virus in Cells and in Living Mice","volume":"5","author":"Rameix-Welti","year":"2014","journal-title":"Nat Commun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890260207","article-title":"Primary Respiratory Syncytial Virus Infection in Mice","volume":"26","author":"Graham","year":"1988","journal-title":"J Med Virol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92000-j","article-title":"Infusion of Fc Gamma Fragments for Treatment of Children With Acute Immune Thrombocytopenic Purpura","volume":"342","author":"Debre","year":"1993","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra993360","article-title":"Immunomodulation of Autoimmune and Inflammatory Diseases With Intravenous Immune Globulin","volume":"345","author":"Kazatchkine","year":"2001","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/aac.32.8.1269","article-title":"Topically Administered Immunoglobulin Reduces Pulmonary Respiratory Syncytial Virus Shedding in Owl Monkeys","volume":"32","author":"Hemming","year":"1988","journal-title":"Antimicrob Agents Chemother"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.61.6.1851-1854.1987","article-title":"Effectiveness of Topically Administered Neutralizing Antibodies in Experimental Immunotherapy of Respiratory Syncytial Virus Infection in Cotton Rats","volume":"61","author":"Prince","year":"1987","journal-title":"J Virol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/21691401.2017.1345927","article-title":"Recent Advances on Biodegradable Polymeric Carrier-Based Mucosal Immunization: An Overview","volume":"46","author":"Kaur","year":"2018","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e3000164","DOI":"10.1371\/journal.pbio.3000164","article-title":"Boosting Subdominant Neutralizing Antibody Responses With a Computationally Designed Epitope-Focused Immunogen","volume":"17","author":"Sesterhenn","year":"2019","journal-title":"PloS Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"eaay5051","DOI":"10.1126\/science.aay5051","article-title":"De Novo Protein Design Enables the Precise Induction of RSV-neutralizing Antibodies","volume":"368","author":"Sesterhenn","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/srep34108","article-title":"Pre-Fusion F is Absent on the Surface of Formalin-Inactivated Respiratory Syncytial Virus","volume":"6","author":"Killikelly","year":"2016","journal-title":"Sci Rep"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2012.01648.x","article-title":"In Vitro and In Vivo Properties Differ Among Liquid Intravenous Immunoglobulin Preparations","volume":"104","author":"Dhainaut","year":"2013","journal-title":"Vox Sang"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2016.10.003","article-title":"Non-Invasive Epicutaneous Vaccine Against Respiratory Syncytial Virus: Preclinical Proof of Concept","volume":"243","author":"Herve","year":"2016","journal-title":"J Control Release"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.683902\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T06:47:14Z","timestamp":1623048434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.683902\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,7]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2021.683902"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.683902","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,7]]},"article-number":"683902"}}